The chart below shows how CTSH performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CTSH sees a +0.63% change in stock price 10 days leading up to the earnings, and a +1.38% change 10 days following the report. On the earnings day itself, the stock moves by +0.73%. This data can give you a slight idea of what to expect for the next quarter's release.
Positive
Third Quarter Revenue Increase: 1. Revenue Growth: Cognizant reported third quarter revenue of $5 billion, reflecting a sequential growth of 3.5% in constant currency, driven by strong performance in Health Sciences and Financial Services.
Adjusted EPS Growth: 2. Adjusted EPS Increase: The adjusted earnings per share (EPS) grew approximately 7% year-over-year, marking the fourth consecutive quarter of year-over-year growth, with year-to-date EPS growth at approximately 5%.
Health Sciences Growth: 3. Strong Health Sciences Performance: The Health Sciences segment experienced a robust year-over-year growth of 7.6% in constant currency, supported by strong demand for differentiated offerings.
Large Deal Success: 4. Large Deal Momentum: Cognizant signed six large deals in the quarter, each with a total contract value of $100 million or more, bringing the year-to-date total to 19 such deals, surpassing the 17 signed in all of 2023.
Shareholder Returns Overview: 5. Shareholder Returns: The company returned $391 million to shareholders in the quarter, including $242 million through share repurchases and $149 million in dividends, with a total year-to-date return of approximately $900 million.
Negative
CMT Revenue Decline: 1. Declining Customer Segment: The Communications, Media, and Technology (CMT) segment experienced a 4% year-over-year decline in revenue, indicating ongoing challenges in discretionary spending within this sector.
Flat Bookings Performance: 2. Stagnant Bookings: Third quarter bookings were roughly flat year-over-year, with trailing 12-month bookings down 2% year-over-year, reflecting a lack of growth momentum in securing new contracts.
Cost Impact on Margins: 3. Increased Costs Impacting Margins: The company incurred $33 million in costs related to the NextGen initiative, negatively impacting GAAP operating margin by approximately 70 basis points, highlighting the financial strain from ongoing investments.
Cash Flow Strain: 4. Cash Flow Concerns: Despite a year-to-date free cash flow of approximately $1 billion, the company faced a significant $360 million payment to Indian tax authorities, which could strain future cash flow availability.
European Revenue Decline: 5. Geographic Revenue Decline: Revenue from Europe declined about 2% year-over-year, impacted by reduced discretionary spending, suggesting challenges in maintaining growth in this key market.
Cognizant Technology Solutions Corporation (CTSH) Q3 2024 Earnings Call Transcript
CTSH.O
1.34%